NYSE:STJ - 2007840 Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$80.82
+0.30 (1.20%)
Get New 2007840 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STJ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for 2007840 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $80.82.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in 2007840. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/22/2016BarclaysReiterated RatingEqual Weight$83.00N/A
i
10/11/2016CowenReiterated RatingBuy$85.00N/A
i
Rating by Josh Jennings at Cowen Inc
9/12/2016Jefferies Financial GroupReiterated RatingHold$60.00N/A
i
8/28/2016ArgusReiterated RatingHoldN/A
i
8/28/2016Credit Suisse GroupReiterated RatingNeutral$81.00N/A
i
8/15/2016BarclaysReiterated RatingEqual Weight$83.00N/A
i
7/21/2016BarclaysBoost Price TargetEqual Weight$80.00 ➝ $83.00N/A
i
Rating by Matthew Taylor at Barclays PLC
7/21/2016SVB LeerinkReiterated RatingHold$85.00N/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
7/20/2016Canaccord GenuitySet Price TargetHold$85.00N/A
i
Rating by ">Jason Mills at Canaccord Genuity
7/17/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
7/15/2016WedbushDowngradeOutperform ➝ Neutral$70.00 ➝ $84.00N/A
i
Rating by Levy. T at Wedbush
7/11/2016SVB LeerinkDowngradeOutperform ➝ Market PerformN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
5/12/2016UBS GroupDowngradeBuy ➝ NeutralN/A
i
5/11/2016BarclaysDowngradeOverweight ➝ Equal Weight$74.00 ➝ $80.00N/A
i
Rating by Matthew Taylor at Barclays PLC
5/10/2016SunTrust BanksDowngradeBuy ➝ Neutral$70.00 ➝ $80.00N/A
i
5/3/2016Credit Suisse GroupDowngradeOutperform ➝ Neutral$67.00 ➝ $81.00N/A
i
5/2/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$67.00 ➝ $81.00N/A
i
5/2/2016ArgusReiterated RatingHoldN/A
i
4/30/2016Canaccord GenuityReiterated RatingHoldN/A
i
Rating by Jason Mills at Canaccord Genuity
4/30/2016Wells Fargo & CompanyReiterated RatingHoldN/A
i
Rating by Larry Biegelsen at Wells Fargo & Company
4/29/2016JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$66.00 ➝ $82.50N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
4/29/2016William BlairDowngradeOutperform ➝ Market PerformN/A
i
Rating by B. Andrew at William Blair
4/29/2016Needham & Company LLCDowngradeBuy ➝ HoldN/A
i
Rating by Michael Matson at Needham & Company LLC
4/28/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$66.00 ➝ $82.50N/A
i
4/28/2016Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
i
4/23/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Danielle Antalffy at SVB Leerink LLC
4/21/2016WedbushReiterated RatingOutperform$70.00N/A
i
(Data available from 4/21/2016 forward)
2007840 logo
St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company's product categories include tachycardia implantable cardioverter defibrillator systems; atrial fibrillation products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products, and Thoratec products.
Read More

Today's Range

Now: $80.82
$80.82
$80.82

50 Day Range

MA: N/A

52 Week Range

Now: $80.82
$48.83
$84.00

Volume

N/A

Average Volume

8,538,350 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 2007840?

The following Wall Street research analysts have issued stock ratings on 2007840 in the last twelve months:
View the latest analyst ratings for STJ.

What is the current price target for 2007840?

0 Wall Street analysts have set twelve-month price targets for 2007840 in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 2007840 in the next year.
View the latest price targets for STJ.

What is the current consensus analyst rating for 2007840?

2007840 currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STJ.

What other companies compete with 2007840?

How do I contact 2007840's investor relations team?

2007840's physical mailing address is 1 Saint Jude Medical Dr, SAINT PAUL, MN 55117-1789, United States. The medical technology company's listed phone number is +1-651-7562000. The official website for 2007840 is www.sjm.com.